A changing treatment landscape for multiple sclerosis: challenges and opportunities
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A changing treatment landscape for multiple sclerosis: challenges and opportunities
Authors
Keywords
-
Journal
JOURNAL OF INTERNAL MEDICINE
Volume 275, Issue 4, Pages 364-381
Publisher
Wiley
Online
2014-01-20
DOI
10.1111/joim.12204
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adherence to Multiple Sclerosis Disease-Modifying Therapies in Ontario is Low
- (2014) Janice Wong et al. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
- Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis
- (2013) Valérie Jolivel et al. BRAIN
- Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
- (2013) Ralf Gold et al. LANCET
- Magnetic resonance imaging outcomes from a phase III trial of teriflunomide
- (2013) Jerry S Wolinsky et al. Multiple Sclerosis Journal
- Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
- (2013) Patrick Vermersch et al. Multiple Sclerosis Journal
- Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis
- (2013) Markus Axelsson et al. Multiple Sclerosis Journal
- Intense Inflammation and Nerve Damage in Early Multiple Sclerosis Subsides at Older Age: A Reflection by Cerebrospinal Fluid Biomarkers
- (2013) Mohsen Khademi et al. PLoS One
- Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination
- (2012) Wolfgang Brück et al. ACTA NEUROPATHOLOGICA
- Antibody-independent B cell effector functions in relapsing remitting Multiple Sclerosis: Clues to increased inflammatory and reduced regulatory B cell capacity
- (2012) Sara J. Ireland et al. AUTOIMMUNITY
- Glatiramer acetate for treatment of relapsing–remitting multiple sclerosis
- (2012) Kenneth P Johnson Expert Review of Neurotherapeutics
- Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis
- (2012) Afsaneh Shirani et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects
- (2012) Jeffrey A Cohen et al. LANCET NEUROLOGY
- Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study
- (2012) Virginia Devonshire et al. LANCET NEUROLOGY
- Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs
- (2012) H Tedeholm et al. Multiple Sclerosis Journal
- Progressive multiple sclerosis: pathology and pathogenesis
- (2012) Hans Lassmann et al. Nature Reviews Neurology
- Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review
- (2012) E. Lu et al. NEUROLOGY
- Fingolimod-associated macular edema: Incidence, detection, and management
- (2012) N. Jain et al. NEUROLOGY
- Alemtuzumab more effective than interferon -1a at 5-year follow-up of CAMMS223 Clinical Trial
- (2012) A. J. Coles et al. NEUROLOGY
- Fingolimod for Multiple Sclerosis
- (2012) Daniel Pelletier et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
- (2012) Giancarlo Comi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Natalizumab on Circulating CD4+ T-Cells in Multiple Sclerosis
- (2012) Lars Börnsen et al. PLoS One
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
- (2011) Chris H. Polman et al. ANNALS OF NEUROLOGY
- Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis
- (2011) Anna Karin Hedström et al. BRAIN
- Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
- (2011) Ralf A. Linker et al. BRAIN
- Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
- (2011) Ludwig Kappos et al. LANCET
- Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis
- (2011) A Scott Nielsen et al. Multiple Sclerosis Journal
- A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis
- (2011) Carolina Holmén et al. Multiple Sclerosis Journal
- Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
- (2011) Stephen Sawcer et al. NATURE
- Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
- (2011) P. W. O'Connor et al. NEUROLOGY
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Fumaric Acid Esters in the R6/2 and YAC128 Models of Huntington's Disease
- (2011) Gisa Ellrichmann et al. PLoS One
- Natalizumab dosage suspension: Are we helping or hurting?
- (2010) Timothy W. West et al. ANNALS OF NEUROLOGY
- Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
- (2010) Martin Gunnarsson et al. ANNALS OF NEUROLOGY
- Anti-JC virus antibodies: Implications for PML Risk Stratification
- (2010) Leonid Gorelik et al. ANNALS OF NEUROLOGY
- Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple Sclerosis
- (2010) Laura Piccio et al. ARCHIVES OF NEUROLOGY
- Evidence for a two-stage disability progression in multiple sclerosis
- (2010) E. Leray et al. BRAIN
- Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
- (2010) Daniel Wynn et al. LANCET NEUROLOGY
- Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis
- (2010) Chen S Tan et al. LANCET NEUROLOGY
- Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis
- (2010) Emma C Tallantyre et al. Multiple Sclerosis Journal
- Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course
- (2010) Mohsen Khademi et al. Multiple Sclerosis Journal
- Environmental factors and their timing in adult-onset multiple sclerosis
- (2010) Adam E. Handel et al. Nature Reviews Neurology
- Breakthrough disease during interferon- therapy in MS: No signs of impaired biologic response
- (2010) D. Hesse et al. NEUROLOGY
- Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis
- (2010) M. Mehling et al. NEUROLOGY
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
- (2009) Kathleen Hawker et al. ANNALS OF NEUROLOGY
- The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL
- (2009) M. Hutchinson et al. JOURNAL OF NEUROLOGY
- Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis
- (2009) Richard A Rudick et al. LANCET NEUROLOGY
- Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study
- (2009) Richard K Burt et al. LANCET NEUROLOGY
- Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
- (2009) Ludwig Kappos et al. LANCET NEUROLOGY
- 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
- (2009) Paul O'Connor et al. LANCET NEUROLOGY
- Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells
- (2009) P. Kivisakk et al. NEUROLOGY
- Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
- (2008) G Comi et al. LANCET
- Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
- (2008) Ludwig Kappos et al. LANCET
- Multiple sclerosis
- (2008) Alastair Compston et al. LANCET
- Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
- (2008) Daniel D Mikol et al. LANCET NEUROLOGY
- B cells and multiple sclerosis
- (2008) Diego Franciotta et al. LANCET NEUROLOGY
- FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis
- (2008) M. Mehling et al. NEUROLOGY
- Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells
- (2008) Max-Philipp Stenner et al. PLoS One
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now